MSP nanopores and related methods

US9540422B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9540422-B2
Application numberUS-201614993952-A
CountryUS
Kind codeB2
Filing dateJan 12, 2016
Priority dateSep 22, 2008
Publication dateJan 10, 2017
Grant dateJan 10, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.

First claim

Opening claim text (preview).

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1. A Mycobacterium smegmatis porin A (MspA) comprising an MspA monomer, wherein the MspA monomer comprises a variant of the sequence in SEQ ID NO: 1, and wherein the variant comprises (i) amino acids with a neutral charge at positions 90 and 91 and (ii) an amino acid with a positive charge at one or more of amino acid positions 118, 134, and 139. 2. The MspA of claim 1 , wherein the variant comprises an amino acid with a positive charge at position 118. 3. The MspA of claim 1 , wherein the variant comprises an amino acid with a positive charge at positions 118, 134, and 139. 4. The MspA of claim 1 , wherein the variant comprises arginine at position 118. 5. The MspA of claim 1 , wherein the variant comprises lysine at position 139. 6. The MspA of claim 1 , wherein the variant comprises arginine at position 134. 7. The MspA of claim 1 , wherein the variant comprises arginine at position 118 and lysine at position 139. 8. The MspA of claim 3 , wherein the variant comprises arginine at position 118, arginine at position 134, and lysine at position 139. 9. The MspA of claim 1 , wherein the variant comprises asparagine or glutamine at position 90 and asparagine or glutamine at position 91. 10. The MspA of claim 1 , wherein the variant comprises asparagine at positions 90 and 91. 11. The MspA of claim 1 , wherein the variant comprises glutamine at positions 90 and 91. 12. The MspA of claim 1 , wherein the variant further comprises an amino acid substitution at position 88. 13. The MspA of claim 3 , wherein the variant further comprises an amino acid substitution at position 88. 14. The MspA of claim 9 , wherein the variant further comprises an amino acid substitution at position 88. 15. The MspA of claim 1 , wherein the variant further comprises an amino acid substitution at position 105. 16. The MspA of claim 1 , wherein the variant furthercomprises an amino acid substitution at position 108. 17. The MspA of claim 1 , wherein the variant further comprises an amino acid with a positive charge at position 126. 18. The MspA of claim 1 , wherein the variant further comprises aspartic acid at position 93. 19. The MspA of claim 3 , wherein the variant further comprises aspartic acid at position 93. 20. The MspA of claim 9 , wherein the variant comprises aspartic acid at position 93. 21. The MspA of claim 1 , wherein the variant comprises asparagine at positions 90 and 91, arginine at positions 118 and 134, and lysine at position 139, and further comprises asparagine at position 93. 22. The MspA of claim 1 , wherein the MspA further comprises a second MspA monomer, and wherein the MspA monomer is connected to the second MspA monomer by one or more amino acid linkers.

Assignees

Inventors

Classifications

  • Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title

  • C07K14/35Primary

    from Mycobacteriaceae (F) · CPC title

  • Microapparatus (sample containers with integrated microfluidic structures B01L3/5027) · CPC title

  • Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves · CPC title

  • C12Q1/6869Primary

    Methods for sequencing · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9540422B2 cover?
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains…
Who is the assignee on this patent?
Univ Washington, Uab Res Found
What technology area does this patent fall under?
Primary CPC classification C07K14/35. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).